Vaxxinity to Present at Upcoming November Medical and Investor Conferences
November 13, 2023 18:50 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and...
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 08, 2023 08:30 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for...
Vaxxinity to Present at Upcoming Investor Conferences in September
August 29, 2023 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief...
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
August 10, 2023 08:00 ET
|
Vaxxinity, Inc.
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the most advanced active immunotherapy targeting beta-amyloid in the...
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for...
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
July 27, 2023 16:30 ET
|
Vaxxinity, Inc.
Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc....
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients
July 17, 2023 08:00 ET
|
Vaxxinity, Inc.
Disease-modifying candidate UB-312 demonstrated target engagement of aggregated alpha-synuclein in cerebrospinal fluid of Parkinson’s patients Data provide validation of the Vaxxinity platform’s...
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease
June 22, 2023 08:00 ET
|
Vaxxinity, Inc.
UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions from Phase 1 Part A and preclinical studies,...
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported...
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
March 28, 2023 08:00 ET
|
Vaxxinity, Inc.
Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine...